ArticleCurrent medical imaging2026
PRAD-Hybrid CNN (PRADHC): A Deep Learning Model for Assisted Diagnosis of Prostate Cancer on MRI
Article in Current medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer is a prevalent malignancy in males, with prostate MRI imaging as the primary diagnostic method. However, this method is subjective and can miss early-stage cancers, necessitating more efficient diagnostic techniques.
methodIn this study, we introduced the PRAD-Hybrid CNN (Prostate Adenocarcinoma Hybrid Convolutional Neural Network, PRADHC) model, a novel amalgamation of EfficientNet and Residual Blocks, which was developed and validated on 1,528 MRI images from 64 patients. By strategically increasing the number of Convolutional Neural Network (CNN) layers in the EfficientNet architecture, our model improved the diagnostic accuracy inherent to the original EfficientNet. Additionally, the integration of Residual Networks (ResNet) successfully mitigated the gradient vanishing issue often encountered during the training of deeper models, thereby significantly enhancing training accuracy. This innovative model, thus, offers clinicians an efficacious tool for assisted diagnosis.
resultThe PRADHC model, upon validation, achieved an accuracy of 99.34% and an AUC of 99.34%, a 4% improvement over the conventional EfficientNet. The baseline elementary CNN model achieved 95.72% accuracy and 96.74% AUC, which are still lower than the PRADHC model. DISCUSSION: The superior performance of PRADHC can be attributed to the synergistic integration of EfficientNet’s multi-scale feature extraction and residual learning, which facilitates deeper network optimization without degradation. Compared with single-architecture CNN models, the hybrid design enhances robustness to MRI appearance variability and improves discrimination between malignant and non-significant prostate tissue
conclusionThis study introduces a novel deep learning model specifically designed for automated prostate cancer diagnosis. This model aims to enhance diagnostic accuracy, especially in the early stages of the disease. Such advancements have the potential to enhance the diagnostic proficiency of both radiologists and urologists, enabling more informed treatment planning. However, it is imperative to acknowledge that false-positive lesion detections remain a limitation of AI-assisted diagnostic tools. Nevertheless, this system can serve as a valuable supplementary instrument for radiologists in their diagnostic endeavors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.